AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.350

+0.0300.24%

Volume:839.62K

Turnover:10.38M

Market Cap:1.56B

PE:53.07

High:12.680

Open:12.200

Low:12.070

Close:12.320

52wk High:22.985

52wk Low:8.610

Shares:126.64M

Float Shares:108.39M

Volume Ratio:1.37

T/O Rate:0.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.233

EPS(LYR):0.233

ROE:8.67%

ROA:3.66%

PB:4.62

PE(LYR):53.07

Loading ...

Overview Company News Filings

Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk

Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset

Simply Wall St.

BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination

Neuren Partner Plans to Request Re-examination of European Authority's Opinion on Trofinetide Marketing Authorization Application

MT Newswires Live

How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress

Simply Wall St.

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality Concerns

Simply Wall St.

Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%

MT Newswires Live

Is Neuren’s 5 Percent Share Buyback Altering The Investment Case For Neuren Pharmaceuticals (ASX:NEU)?

Simply Wall St.

Assessing NewMarket (NEU) Valuation As Shares Trade Near Half Of DCF Fair Value Estimate

Simply Wall St.

NewMarket (NEU) Margin Decline Challenges Long Term Earnings Growth Narrative

Simply Wall St.

Neuren Pharmaceuticals (ASX:NEU) Valuation Check As New Share Buy-Back Targets 5% Of Share Capital

Simply Wall St.

Earnings Flash (NEU) NewMarket Posts Q4 EPS of $8.65

MT Newswires Live

Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program

MT Newswires Live

Neuren Pharmaceuticals - Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back

THOMSON REUTERS

Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies

MT Newswires Live

BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts

Neuren Doses First Patient in Drug Candidate Trial for Treatment of Neurological Disorder

MT Newswires Live

Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch

Simply Wall St.

BUZZ-Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.35,"timestamp":1772773920000,"preClose":12.32,"halted":0,"volume":839622,"delay":0,"changeRate":0.002435064935064883,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":0.2327,"marketStatus":"Market Closed","change":0.03,"latestTime":"03-06 16:12:00 AEDT","open":12.2,"high":12.68,"low":12.07,"amount":10384816,"amplitude":0.049513,"askPrice":12.59,"askSize":1000,"bidPrice":12.26,"bidSize":1624,"shortable":3,"etf":0,"ttmEps":0.2327,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1773010800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":12.32,"openAndCloseTimeList":[[1772751600000,1772773200000]],"volumeRatio":1.372543634391313,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NEU.AU","preClose":12.32,"auctionPrice":12.35,"auctionVolume":174941,"auction":3,"marketStatus":"盘后竞价","timestamp":1772773814920}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"3.66%","roe":"8.67%","lyrEps":0.2327,"volumeRatio":1.372543634391313,"shares":126639526,"dividePrice":0,"high":12.68,"amplitude":0.049513,"preClose":12.32,"low":12.07,"week52Low":8.61,"pbRate":"4.62","psRate":"24.19","week52High":22.985,"institutionHeld":0,"latestPrice":12.35,"committee":0.237805,"eps":0.2327,"divideRate":0,"volume":839622,"delay":0,"ttmEps":0.2327,"open":12.2,"prevYearClose":18.61,"prevWeekClose":13.05,"prevMonthClose":13.05,"prevQuarterClose":18.61,"fiveDayClose":13.05,"twentyDayClose":12.52,"sixtyDayClose":19.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616137072","title":"Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2616137072","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616137072?lang=en_us&edition=fundamental","pubTime":"2026-03-04 07:08","pubTimestamp":1772579280,"startTime":"0","endTime":"0","summary":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2616346369","title":"Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2616346369","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616346369?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:25","pubTimestamp":1772533526,"startTime":"0","endTime":"0","summary":"Earnings trigger and why Neuren is on radar\nNeuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year.\nSee our latest analysis for Neuren Pharmaceuticals.\nThe share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","NEU.AU"],"gpt_icon":0},{"id":"2616925273","title":"BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination","url":"https://stock-news.laohu8.com/highlight/detail?id=2616925273","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616925273?lang=en_us&edition=fundamental","pubTime":"2026-03-03 11:53","pubTimestamp":1772510032,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination** Shares of Neuren Pharmaceuticals NEU.AX fall 8% to A$12.67, on track for their weakest session since February 5** The biopharma firm says its partner, Acadia Pharmaceuticals ACAD.O, confirms plan to request re-examination of opinion adopted by Committee for Medicinal Products for Human Use of the European Medicines Agency ** Re-examination regarding the marketing of trofinetide for the treatment of Rett syndrome in patients two years and older - co** Australian healthcare stocks .AXHJ down 1.5%, in line with broader benchmark .AXJO which is down 1.2%** YTD, stock down 31.9%, including the day's move  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4N3ZR0BD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","ACAD","LU2065171311.SGD","LU2065171402.SGD","BK7508","LU2065170008.USD","BK7096","LU2065169927.USD","BK4139"],"gpt_icon":0},{"id":"2616609843","title":"Neuren Partner Plans to Request Re-examination of European Authority's Opinion on Trofinetide Marketing Authorization Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2616609843","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616609843?lang=en_us&edition=fundamental","pubTime":"2026-03-03 07:36","pubTimestamp":1772494615,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its partner, Acadia Pharmaceuticals, confirmed that it plans to request a re-examination of the European Medicines Agency's Committee for Medicinal Products for Human Use's opinion regarding the marketing authorization application for trofinetide for the treatment of Rett syndrome in patients aged two years and older, according to a Tuesday Australian bourse filing.The committee issued a refusal, saying that the treatment effect observed with trofinetide after 12 weeks, while measurable, was viewed as limited in magnitude, that the Lavender clinical trial did not capture all core symptoms of Rett syndrome, and that the assessment of longerterm outcomes was influenced by patient discontinuations over time.Trofinetide is approved in the US, Canada, and Israel, per the filing.Neuren Pharmaceuticals' shares fell 5% in early trading on Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2616338779","title":"How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2616338779","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616338779?lang=en_us&edition=fundamental","pubTime":"2026-03-02 15:13","pubTimestamp":1772435590,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive announcement.\nDespite lower year-on-year earnings, Neuren highlighted increased DAYBUE royalties, a new share buy-back program, and progress in its NNZ-2591 pipeline, including an FDA Fast Track designation, underscoring the company’s focus on advancing its rare neurological disorder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","BK4097","BK7508","BK4109","BK4211","LU2065732104.USD","PRGS","BK7096","NEU.AU","ISBC"],"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","BK7096","BK7509","HCAR","HLS.AU","XKO.AU","RHC.AU","BK4588","REG.AU","SHL.AU","XAO.AU","XBI","BK7501","BK7124","MSB.AU","ANN.AU","BK7007","BK7103","IDX.AU","BK4585","BK4581","XJO.AU","CU6.AU","BK7089","FPH.AU","CUV.AU","COH.AU","LABU","TLX.AU","MPL.AU","NHF.AU","BK7067","NEU.AU","BK7508","BK7113","XLV","CSL.AU","MVF.AU","SIG.AU","IMM.AU","BK7126"],"gpt_icon":0},{"id":"2616447198","title":"Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2616447198","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616447198?lang=en_us&edition=fundamental","pubTime":"2026-03-01 05:29","pubTimestamp":1772314142,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) has opened FY 2025 with first half revenue of A$28.3 million and basic EPS of A$0.12, setting a different tone from the prior half, when the company recorded A$192.5 million of revenue and basic EPS of A$1.05. The company has seen revenue move from A$26.2 million and basic EPS of A$0.06 in the first half of FY 2024 to A$28.3 million and A$0.12 in the latest period. Trailing twelve month EPS sits at A$1.17 on revenue of A$218.9 million, giving investors a clear...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-fy-2025-margin-strength-tests-earning","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-fy-2025-margin-strength-tests-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2614060270","title":"Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614060270","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614060270?lang=en_us&edition=fundamental","pubTime":"2026-02-26 12:03","pubTimestamp":1772078605,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2612287110","title":"Is Neuren’s 5 Percent Share Buyback Altering The Investment Case For Neuren Pharmaceuticals (ASX:NEU)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2612287110","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612287110?lang=en_us&edition=fundamental","pubTime":"2026-02-20 00:40","pubTimestamp":1771519229,"startTime":"0","endTime":"0","summary":"On 11 February 2026, Neuren Pharmaceuticals Limited (ASX:NEU) announced a share repurchase program authorizing the buyback and cancellation of up to 6,350,631 shares, or 5% of its 126,639,526 issued shares, with the program running until 2 March 2027.\nThis move reduces the future share count relative to current levels, which can increase each remaining share’s claim on any future earnings and cash flows.\nWe’ll now examine how Neuren’s decision to buy back and cancel up to 5% of its shares...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/is-neurens-5-percent-share-buyback-altering-the-investment-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/is-neurens-5-percent-share-buyback-altering-the-investment-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","BK7096","NEU","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2612487290","title":"Assessing NewMarket (NEU) Valuation As Shares Trade Near Half Of DCF Fair Value Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612487290","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612487290?lang=en_us&edition=fundamental","pubTime":"2026-02-17 04:16","pubTimestamp":1771272990,"startTime":"0","endTime":"0","summary":"What recent returns say about NewMarket\nWith no single headline event setting the tone, NewMarket (NEU) has been moving under the radar. The stock has shown a 0.7% decline over the past day and weaker performance over the past week.\nSee our latest analysis for NewMarket.\nBeyond the latest 0.7% daily share price decline, NewMarket’s recent 7 day and 90 day share price returns of 17.0% and 21.1% point to fading short term momentum. At the same time, 1 year and 3 year total shareholder returns...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/assessing-newmarket-neu-valuation-as-shares-trade-near-half","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/assessing-newmarket-neu-valuation-as-shares-trade-near-half","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","NEU.AU","NEU","BK4109","BK7096","DCF"],"gpt_icon":0},{"id":"2611185336","title":"NewMarket (NEU) Margin Decline Challenges Long Term Earnings Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2611185336","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611185336?lang=en_us&edition=fundamental","pubTime":"2026-02-13 10:34","pubTimestamp":1770950083,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) has wrapped up FY 2025 with fourth quarter revenue of US$635.4 million and basic EPS of US$8.65, anchored by net income of US$81.3 million, alongside trailing twelve month revenue of US$2.7 billion and basic EPS of US$44.44. Over recent quarters, the company has seen revenue move from US$700.9 million and EPS of US$13.26 in Q1 2025 through to US$698.5 million and EPS of US$11.84 in Q2, US$690.3 million and EPS of US$10.67 in Q3, and then US$635.4 million and EPS of US$8.65 in...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-long-term-earnings-g","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-long-term-earnings-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","NEU.AU"],"gpt_icon":0},{"id":"2611896051","title":"Neuren Pharmaceuticals (ASX:NEU) Valuation Check As New Share Buy-Back Targets 5% Of Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2611896051","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611896051?lang=en_us&edition=fundamental","pubTime":"2026-02-13 10:30","pubTimestamp":1770949801,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) has announced a new share buy-back program, authorising repurchases of up to 6,350,631 shares, or 5% of its issued capital, through to March 2027.\nSee our latest analysis for Neuren Pharmaceuticals.\nThe buy-back comes after a sharp 30 day share price return of around a 30% decline and a 90 day share price return of about a 29% decline, even though the 1 year and multi year total shareholder returns remain positive and very strong. This suggests recent selling...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-valuation-check-as-new-share-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-valuation-check-as-new-share-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","DCF","BK7508","NEU.AU","NEU","BK7096"],"gpt_icon":0},{"id":"2610496295","title":"Earnings Flash (NEU) NewMarket Posts Q4 EPS of $8.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2610496295","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610496295?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:24","pubTimestamp":1770848670,"startTime":"0","endTime":"0","summary":"Earnings Flash (NEU) NewMarket Posts Q4 EPS of $8.65","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU","NEU.AU"],"gpt_icon":0},{"id":"2610983756","title":"Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2610983756","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610983756?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:47","pubTimestamp":1770792440,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  disclosed a new on-market share buy-back program with a period of up to 12 months, which will be conducted under section 65 of the New Zealand Companies Act 1993 and will not exceed 5% of the total shares on issue 12 months before the commencement of the buy-back, according to a Wednesday Australian bourse filing.\"The board views the current share price as materially undervaluing Neuren's assets, relative to internal analyses and the range of recently published analyst valuations,\" said Chair Patrick Davies.Shares purchased under the buy-back will be cancelled upon acquisition, reducing the number of shares on issue, and the number of shares purchased under the buy-back will be less than the \"10/12\" limit prescribed in the Australian Corporations Act and will not require shareholder approval, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2610988807","title":"Neuren Pharmaceuticals -  Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2610988807","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610988807?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:00","pubTimestamp":1770789635,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z61NR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2609384536","title":"Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2609384536","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609384536?lang=en_us&edition=fundamental","pubTime":"2026-02-06 08:13","pubTimestamp":1770336816,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  facing regulatory uncertainty in the European Union  for its investigational drug trofinetide to treat Rett syndrome may delay royalties from sales in the region, Jefferies said in a note on Thursday.The European Medicines Agency  Committee for Medicinal Products for Human Use  gave a negative trend vote this week on the drug candidate's market authorization application, possibly due to concerns about the effect size in the confirmatory trial.Jefferies said the negative trend vote is an early indication that the regulatory authority might issue a negative opinion on the application at the final vote.The investment firm now expects royalties from EU sales of trofinetide to kick in the fourth quarter of fiscal 2026, and not second quarter.Meanwhile, it projects Neuren's experimental drug NNZ-2591 for treating Pitt-Hopkins Syndrome, a rare neurodevelopmental disorder, will receive reimbursement approval in the US in fiscal 2029.Jefferies lowered the company's fisca","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","NEU.AU","EMA.AU","CHMP","BK4156","BK7129","EMA","BK7096","BK7508","BK4087"],"gpt_icon":0},{"id":"2609533926","title":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533926","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533926?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:39","pubTimestamp":1770334764,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cutsUpdates** Neuren Pharmaceuticals NEU.AX slips 3.41% to A$12.750, heading toward a tenth straight day of losses** St","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL6N3Z11HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","LU2065171311.SGD","BK4139","JEF","BK4559","BK7096","BK7508","LU2065170008.USD","NEU.AU","LU2065171402.SGD","LU2065169927.USD","ACAD"],"gpt_icon":0},{"id":"2609533478","title":"Neuren Doses First Patient in Drug Candidate Trial for Treatment of Neurological Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533478","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533478?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:15","pubTimestamp":1770333305,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  dosed the first patient in its Koala Phase 3 clinical trial of its drug candidate NNZ-2591 for the treatment of Phelan-McDermid syndrome , a neurological disorder with no treatment options, according to a Friday filing with the Australian bourse.The trial evaluates the safety and efficacy of NNZ-2591 in about 160 children aged three to 12 years with PMS, the filing said.Most of the participants in the trial are expected to start dosing or start screening during February and March, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2609756530","title":"Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch","url":"https://stock-news.laohu8.com/highlight/detail?id=2609756530","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609756530?lang=en_us&edition=fundamental","pubTime":"2026-02-06 04:55","pubTimestamp":1770324925,"startTime":"0","endTime":"0","summary":"The Neuren Pharmaceuticals Limited ( ASX:NEU ) share price has fared very poorly over the last month, falling by a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/slammed-30-neuren-pharmaceuticals-limited-asxneu-screens-wel","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/slammed-30-neuren-pharmaceuticals-limited-asxneu-screens-wel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","NEU","NEU.AU","BK4109","BK7096"],"gpt_icon":0},{"id":"2609346456","title":"BUZZ-Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=2609346456","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609346456?lang=en_us&edition=fundamental","pubTime":"2026-02-05 10:51","pubTimestamp":1770259908,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles** Shares of Neuren Pharmaceuticals NEU.AX plunges as much as 10.7% to A$13.06** Biotech says FDA will only provide written responses for NNZ-2591 drug development meetings, not face-to-face discussions as requested** Drug targets hypoxic ischemic encephalopathy and Pitt Hopkins syndrome** Stock fell 10% on Feb 3 on setback for Rett treatment drug application from European regulator, trading halt on Feb 4 pending FDA update","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL4N3Z10B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}]}}